GSK and Novartis report earnings
Amgen adopts a two-price strategy for first Humira biosimilar, Amjevita
Legislative hurdles anticipated for biopharma in 2023
Bayer under investor pressure to speed up CEO changeover
*please scroll down for all the latest news*
